Document is current
Any future updates will be listed below
-
Authors
Rauch, Susanne
Roth, Nicole
Schwendt, Kim
Fotin-Mleczek, Mariola
Mueller, Stefan O.
Petsch, Benjamin
-
Funding
Funding for this research was provided by:
Coalition for Epidemic Preparedness Innovations
- License Information
-
More Information
Article History
Received: 12 December 2020
Accepted: 7 March 2021
First Online: 16 April 2021
Competing interests
: M.F.-M. is a management board member and employee of CureVac AG, Tuebingen Germany. S.R., B.P., N.R., K.S. and S.O.M. are employees of CureVac AG, Tuebingen Germany, a publically listed company developing RNA-based vaccines and immunotherapeutics. All authors may hold shares or stock options in the company. S.R., B.P., N.R., K.S., M.F.-M. inventors on several patents on mRNA vaccination and use thereof.
